CABA

Cabaletta Bio, Inc. (CABA) - Q2 2026 10-Q Summary

Business Context and Reporting Period

Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. The primary product candidate is resecabtagene autoleucel (rese-cel), a CD19-CAR T cell therapy designed to reset the immune system. This report covers the quarterly period ended June 30, 2026. The company operates in a single segment focused on research and development (R&D) and has no commercial product revenue.

Key Financial Metrics

Note: The company reported no revenue. All financial figures are in thousands of USD.

Material Changes vs. Prior Period

• Increased R&D Spend: Research and development expenses increased by $6.8 million in Q2 2026 compared to Q2 2025. This was driven by a $3.0 million increase in license costs (milestone payments to IASO and Oxford), a $2.4 million increase in clinical trial costs due to higher enrollment, and a $2.2 million increase in manufacturing costs for commercial readiness.
• Financing Activity: The company significantly bolstered its liquidity in Q2 2026. In May 2026, it raised approximately $140.2 million through a public offering of 51.7 million shares. Additionally, the company raised $28.7 million via its At-The-Market (ATM) program and $13.2 million from warrant exercises during the six-month period.
• Cash Position: Cash and cash equivalents increased from $82.9 million at year-end 2025 to $225.1 million at June 30, 2026, primarily due to the equity financings and the maturity of short-term investments.
• Stock Count: Outstanding common shares increased from 100.5 million (Dec 31, 2025) to 167.7 million (June 30, 2026) due to the May 2026 offering and ATM sales.

Guidance, Outlook, and Risks

• Clinical Progress: The company is advancing the RESET clinical program for rese-cel across multiple indications (Myositis, Systemic Sclerosis, Lupus, Myasthenia Gravis, Pemphigus Vulgaris). Registrational cohorts for Myositis and Systemic Sclerosis are underway or planned. Data presented at EULAR 2026 showed promising efficacy and safety profiles, including responses in patients treated without preconditioning.
• Going Concern Warning: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern. While current cash is expected to fund operations into mid-2027, the company anticipates continuing to incur significant losses and will require substantial additional funding to complete development and commercialization.
• Manufacturing Strategy: The company relies on third-party manufacturers, including Lonza and Cellares. A new agreement with Cellares for automated manufacturing was highlighted as a key step toward scalability.
• Key Risks:
  • Failure to secure additional financing on favorable terms.
  • Regulatory hurdles regarding the use of external controls in single-arm registrational trials.
  • Manufacturing complexities and supply chain dependencies.
  • Potential safety issues (CRS, ICANS) associated with CAR T therapies.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the "mid-2027" cash runway estimate against current burn rates and planned clinical trial costs.
• Financing Needs: Assess the likelihood and terms of future capital raises required to bridge the gap between mid-2027 and potential commercialization.
• Regulatory Pathway: Confirm FDA feedback on the single-arm trial designs and the acceptability of external control data for the Myositis and SSc registrational studies.
• Manufacturing Scalability: Review the status of the Cellares automated manufacturing platform and the transition from clinical to commercial scale production.
• Dilution Impact: Evaluate the impact of the recent share issuances (May 2026 offering and ATM sales) on existing shareholder ownership percentages.